|
| 钙调磷酸酶抑制剂引起骨质疏松分析 |
| Analysis of osteoporosis induced by calcineurin inhibitors |
| |
| DOI：10.3969/j.issn.1006-7108.2025.05.022 |
| 中文关键词: 钙调磷酸酶 骨丢失 骨质疏松 肾性骨病 |
| 英文关键词:calcineurin bone loss osteoporosis renal osteodystrophy |
| 基金项目:山东省自然科学基金项目（ZR2022LZY005） |
|
| 摘要点击次数: 1051 |
| 全文下载次数: 0 |
| 中文摘要: |
| 钙调磷酸酶抑制剂（calcineurin inhibitor，CNI）是移植患者和自身炎症性疾病患者的常用药物，在治疗免疫诱导的疾病中具有较好的疗效。但此类药物副作用也较多。临床上发现，越来越多的患者服用CNI药物后会出现骨质丢失的现象，临床表现为周身关节肌肉的疼痛、身高降低、牙齿脱落、骨折等，且疼痛程度与药物剂量和使用时间相关。笔者主要从CNI的作用机制、CNI相关性骨质疏松的循证及动物实验依据、实验研究以及临床诊断、治疗等方面进行论述，以期为临床上重视和研究CNI导致骨质疏松发病机制，找出针对性的治疗药物，减轻患者的痛苦提供参考和依据。 |
| 英文摘要: |
| Calcineurin inhibitors (CNI) are commonly used drugs for patients undergoing transplantation and those with autoimmune inflammatory diseases, demonstrating good efficacy in treating immune-mediated conditions. However, these drugs also have a range of side effects. Clinically, it has been observed that more and more patients develop bone loss after taking CNI medications. The clinical manifestations include generalized joint and muscle pain, height reduction, tooth loss, and fractures, with the severity of pain related to the dosage and duration of the medication. This paper primarily discusses the mechanism of action of CNIs, evidence of CNI-related osteoporosis from clinical studies and animal experiments, as well as experimental research and clinical diagnosis and treatment. The aim is to provide a reference for better research and use of these drugs in clinical settings, to alleviate patient suffering and improve the quality of life for patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |